New drug combo for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be a type called high-grade serous, high-grade endometrioid, clear cell, or carcinosarcoma.
- Your cancer must have come back after 1 or 2 previous treatments.
- Your cancer must be platinum-sensitive (came back more than 6 months after your last platinum chemo).
- You cannot have had certain previous treatments like a topoisomerase 1 inhibitor or a B7-H4 targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new maintenance treatment (Mo-Rez) for people with advanced ovarian cancer whose tumors do not have a specific DNA repair problem (HRD). It is for those who have finished first-line platinum chemotherapy and had a good response. The goal is to see if Mo-Rez can help keep the cancer from coming back.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.